Save the date! International Monarch Monitoring Blitz: 25 July
For ten days, the International Monarch Monitoring Blitz invites the North American population to locate milkweed plants and look for eggs, caterpillars, chrysalises and butterflies in order to help estimate the size of the monarch's summer population. To take part, you need only transmit your monarch and milkweed plant observations via the Insectarium's Mission Monarch program.
Crucial data for monarch protection
The monarch's population has declined by 90% over the last 25 years, with the population size recorded in Mexico's wintering grounds last winter being the second lowest on record. Several factors are contributing to this sharp decline across the monarch's breeding and migratory range: loss of breeding habitat, pesticides and climate change.
Since monarch and milkweed populations cover a great deal of North America, the participation of the population is essential for deepening our knowledge of these two intimately connected species.
These observations help identify priority areas for monarch conservation and guide concrete actions on the ground. All data collected during the Blitz will be made available through the Trinational Monarch Knowledge Network, hosted on GBIF, where it will support large-scale analyses by scientists, researchers and conservation practitioners.
With monarch conservation gaining momentum across North America, there has never been a better time for communities to get involved. Step outside, connect with nature, and be part of the movement to protect the monarch butterfly!
Quotes
Maxim Larrivée, Director, Insectarium
"The Monarch Blitz is an example where community science – thanks to coordinated local action – can have a true continent-wide impact on the preservation of biodiversity. That collaboration, which brings together Canada, Mexico and the United States Mexico, embodies a real solution for implementing protective measures aimed at conserving the monarch butterfly."
Wendy Caldwell, Executive Director, Monarch Joint Venture
"The Monarch Joint Venture is proud to support the International Monarch Monitoring Blitz, a powerful example of international collaboration to better understand and protect one of North America's most iconic migratory species. Community science plays a vital role in tracking monarch populations and informing conservation action across borders—and every observation counts."
Jerónimo Chávez, Project Manager, Correo Real Program, Profauna A.C.
"An increase in the area occupied by the monarch butterfly on its wintering grounds in Mexico during the 2024–2025 season gave us great joy this year; it provided impetus to step up our commitment to conserve this incredible migratory phenomenon. An important part of the conservation of this species is compiling information all along its migratory journey throughout the year. We are therefore inviting everyone in North America with an interest in the monarch butterfly to join the Monarch Blitz in 2025. In Mexico, the Blitz enables us to map out the local (non-migratory) monarch butterfly populations and to continue promoting their conservation."
Your Time to Shine!
To take part in the Monarch Blitz, please share your observations through one of the participating community science programs below.
Naturalista (mexico.inaturalist.org)
Correo Real Program (correoreal.mx)
United States:
Journey North (journeynorth.org)
Monarch Larva Monitoring Project (mlmp.org)
Western Monarch Milkweed Mapper (monarchmilkweedmapper.org)
iNaturalist (inaturalist.org)
Follow the Monarch Blitz and share your participation in this international conservation effort on social media by using the hashtag #MonarchBlitz!
Organizations United for Monarch Conservation
The Blitz is organized by a collaboration of organizations from across North America, including the Commission for Environmental Cooperation (CEC), the Insectarium | Montréal Espace pour la vie, Environment and Climate Change Canada (ECCC), the Canadian Wildlife Federation (CWF), the Monarch Joint Venture, Journey North, the U.S. Fish and Wildlife Service (USFWS), the Xerces Society for Invertebrate Conservation, Profauna A.C. and Mexico's National Commission of Protected Natural Areas (Conanp).
About Espace pour la vie
Protecting biodiversity and the environment is at the heart of the mission of Espace pour la vie, which is made up of the Biodôme, Biosphère, Insectarium, Jardin botanique and Planétarium. Together, these museums located in Montréal form Canada's largest natural science museum complex, welcoming over 2.4 million visitors each year. In view of the challenges our planet is facing, Espace pour la vie is working to increase its impact by fostering dialogue with communities and taking actions aimed at mobilizing the public behind the socio-ecological transition.
SOURCE Espace pour la vie Montreal
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
3 days ago
- Cision Canada
CABHI launches AgeTech Insights to shape the future of aging Français
TORONTO, Aug. 1, 2025 /CNW/ - The Centre for Aging + Brain Health Innovation (CABHI), powered by Baycrest, launched AgeTech Insights at the Global Dementia Research + Innovation Showcase, its flagship event during the Alzheimer's Association International Conference (AAIC) 2025. The novel hub will help drive Canadian innovation by mobilizing knowledge and sharing market intelligence in the aging and brain health sector. "AgeTech Insights shares critical knowledge with entrepreneurs, investors, innovators, ecosystem builders, and policymakers to gain a deeper understanding of the current technology trends among older persons in Canada and around the world," said Dr. Allison Sekuler, President and Chief Scientist at CABHI and the Baycrest Academy for Research and Education. "These insights will ensure innovations are designed to meet the needs of older persons while advancing economic growth, in line with demographic trends as they shift in our country." As an innovation catalyst, CABHI supports innovators—scientists, researchers, clinicians, startup companies, and healthcare organizations—at all stages of their innovation journey. From helping early-career scientists and researchers join the innovation ecosystem through the CABHI Science Collaborative, to supporting innovators develop, test, and refine their solutions through the NextGen Support Package and Ignite, all the way to helping AgeTech companies with growth and scale through Fuel. AgeTech Insights will complement these efforts by identifying gaps, highlighting trends, and informing the development of age-inclusive solutions. Canada is facing a historic demographic shift with nearly one in five Canadians over the age of 65, and that number is set to rise dramatically. This change is reshaping the country's economy and health systems, creating an urgent demand for innovation in aging and brain health. CABHI's AgeTech Insights is designed to help meet this demand. The announcement took place during the Global Dementia Research + Innovation Showcase, attended by over 300 guests, including Michelle Cooper, Parliamentary Assistant to the Minister of Finance, Member of the Standing Committee on Public Accounts, and Member of Provincial Parliament for Eglinton—Lawrence, and Laura Smith, First Vice-Chair, Standing Committee on Procedure and House Affairs, Parliamentary Assistant to the Minister of Municipal Affairs and Housing (Housing), Member of the Standing Committee on Government, and Member of Provincial Parliament for Thornhill. AgeTech Insights will serve as a national and global knowledge hub to inform scientists, researchers, innovators, entrepreneurs, and policymakers on the needs of older persons while unlocking opportunities in the rapidly growing AgeTech market. "Ontario-made research is driving our economy and improving lives across the province," said Nolan Quinn, Minister of Colleges, Universities, Research and Excellence. "Our government is proud to support the Centre of Aging + Brain Health and commend their newest hub, AgeTech Insights, which will further advance discoveries at postsecondary and research institutions, leading to better, stronger brain health care for seniors in Ontario." AgeTech Insights launched with its first market intelligence report, offering insights into technology use in Canadians aged 50+, shedding light on barriers and enablers, and informing innovators how to apply this intelligence to their work. CABHI will share insights from Canadians aged 50+ through reports and knowledge products in collaboration with national and international ecosystem partners. By tracking, analyzing, and disseminating global trends, AgeTech Insights will influence innovation design, uptake, and policy in Canada, positioning the country as a global AgeTech leader. Learn more about the first AgeTech Insights Report and other knowledge products online on CABHI's website. About the Centre for Aging + Brain Health Innovation: The Centre for Aging + Brain Health Innovation (CABHI), powered by Baycrest, was established in 2015 to support researchers, clinicians, and innovators, as they develop and adopt transformative innovations that improve the lives of older persons, including those impacted by dementia. CABHI is a unique collaboration of healthcare, science, industry, not-for-profit, and government partners. Through its funding programs and tailored acceleration services, including access to diverse end-user groups, CABHI advances transformative aging and brain health innovations across Canada and the world. For more information, visit: About Baycrest: At Baycrest, our vision is a world where every older person lives with purpose, fulfilment and dignity. Baycrest is a global leader in aging and brain health innovation, with over 105 years of expertise in seniors' care and cutting-edge research. Baycrest has been Designated with Exemplary Status by Accreditation Canada, and drives industry-leading care and safety outcomes. As the home of the Centre for Aging + Brain Health Innovation (CABHI) powered by Baycrest, the Baycrest Academy for Research and Education (BARE) and the Canadian Consortium on Neurodegeneration in Aging, Baycrest is at the forefront of dementia research. Affiliated with the University of Toronto, Baycrest's training programs shape the future of care globally, while Baycrest Global Solutions extends its expertise to senior living and healthcare internationally. For more information, visit:
Cision Canada
4 days ago
- Cision Canada
RESEARCH ADVANCES FROM THE 2025 ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE
TORONTO, July 31, 2025 /CNW/ -- New research results reported at the Alzheimer's Association International Conference ® 2025 (AAIC ®) advanced scientific understanding of risk, diagnosis and treatment of Alzheimer's disease and other dementias. Highlights include: Two lifestyle interventions in the U.S. POINTER clinical trial improved cognition in older adults at risk of cognitive decline. A structured intervention with more support and accountability showed greater improvement compared to a self-guided intervention, helping to protect against normal age-related decline for up to two years. The Alzheimer's Association released its first clinical practice guidelines on use of blood biomarker tests by specialists to assist in the diagnosis of Alzheimer's disease. Taking a combination of common drugs to treat blood pressure, cholesterol and diabetes may slow cognitive decline, according to data from five studies. Lead in the atmosphere and environment may be linked to memory problems 50 years later, based on a study of more than 600,000 people. Walking and other lifestyle interventions could benefit people with the strongest known genetic risk for Alzheimer's disease, the APOE4 gene variant. The first results from "real world" studies of new amyloid targeting Alzheimer's drugs confirmed findings from the late-stage clinical trials, and patients expressed satisfaction. Participation in the U.S. Supplemental Nutrition Assistance Program (SNAP) is linked to slower cognitive decline, according to a first-of-its-kind long-term study. New research gives insights into critical sex-based differences in brain health, including how traumatic brain injuries impact women and men differently, and new understanding of cognitive symptoms for women undergoing chemotherapy for breast cancer. AAIC is the premier annual conference for presentation and discussion of the latest Alzheimer's and dementia research. This year's conference in Toronto attracted nearly 19,000 registered attendees and included more than 6,400 scientific submissions. Positive Results from the U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) Study The Alzheimer's Association U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) — a two-year, multi-site clinical trial testing two different lifestyle interventions in a representative population of older adults at risk for cognitive decline and dementia — found that both interventions improved cognition in older adults at risk of cognitive decline. Trial participants in the structured intervention showed greater improvement on global cognition compared to the self-guided intervention, helping to protect against normal age-related decline for up to two years. This means that, relative to the self-guided group, participants in the structured group performed at a level comparable to adults one to nearly two years younger in age — an effect that likely increases resilience against cognitive decline. This extra benefit was similar across all subgroups of U.S. POINTER participants — regardless of sex, ethnicity, genetic risk or heart health (blood pressure, cholesterol, and glucose levels). More than 30% of participants were from groups that have been historically underrepresented in dementia research. Both interventions focused on increasing physical activity, improving nutrition, cognitive and social challenge, and health monitoring. The structured intervention differed from the self-guided intervention in intensity, structure, accountability and the support provided. U.S. POINTER was a large-scale, rigorous, randomized controlled clinical trial. These positive results underscore the message that healthy behavior has a powerful impact on brain health, and encourage us to look at the potential for a combination of a lifestyle program and drug treatment as the next frontier in the fight against cognitive decline and possibly dementia. First Clinical Practice Guideline For Blood Biomarker Tests in Alzheimer's Diagnosis The Alzheimer's Association released its first evidence-based clinical practice guideline (CPG) on the use of blood-based biomarker (BBM) tests at AAIC 2025, a big step toward transforming Alzheimer's diagnosis and management in specialty care settings. The CPG provides rigorous, evidence-based recommendations to help specialist clinicians to use BBM tests more confidently and consistently. The recommendations are aimed at a variety of specialists in settings like neurology, psychiatry, geriatrics and more who diagnose and evaluate cognitive impairment, and are based on a review of available evidence through November 2024. The recommendations suggest that specialists can use BBM tests as a triaging tool in the diagnostic workup of Alzheimer's when they have at least 90% sensitivity and 75% specificity, but a positive triaging test should always be confirmed with more traditional tests like cerebral spinal fluid (CSF) or amyloid positron emission tomography (PET) imaging. The guidelines permit BBM tests with at least 90% sensitivity and 90% specificity to substitute for PET imaging or CSF testing. However, experts caution that many commercially available BBM tests do not yet meet these thresholds. This CPG is part of ALZPro ™ from the Alzheimer's Association, the comprehensive hub of resources and tools for health care professionals and researchers from across disciplines to reduce risk, advance early detection, improve care and expand equitable access for all communities. Combination of Heart-Health Drugs May Also Protect the Brain Taking a combination of common drugs used to treat blood pressure, cholesterol and diabetes may have an added benefit: slower cognitive decline. A study of more than 4,500 older adults showed cognitive test scores similar to people three years younger for participants who took a combination of drugs targeting vascular or metabolic conditions, all of which are known risk factors for dementia. Participants who were on all three of the vascular drugs had the greatest cognitive benefits, and their brains showed fewer signs of Alzheimer's-related changes at autopsy. For those who took only two of the drugs, the most effective pairing for cognitive protection was blood pressure and cholesterol drugs. Lead Pollution Linked to Memory Problems in Older Adults Historic pollution levels from the era of leaded gasoline may be contributing to cognitive issues 50 years later, according to a first-of-its-kind research study. Researchers tracked how exposure to airborne lead from 1960-1974 — when leaded gasoline use was at its highest — impacted brain health later in life. The report estimated that half the U.S. population at that time, more than 170 million people, were exposed to high lead levels in early childhood. The researchers linked the pollution data from the 60s and 70s to a contemporary study conducted between 2012 and 2017. They estimated that 17 to 22% of people living in areas with moderate or high atmospheric lead reported memory issues. While leaded gas has long been phased out, other sources of exposure remain, such as old lead paint, pipes and industrial pollution. Experts say people who had past lead exposure should focus on reducing other risk factors for dementia, including managing high blood pressure, quitting smoking and avoiding social isolation. Lifestyle Change Benefits May Be Strongest for Carriers of Alzheimer's Risk Gene People with a higher genetic risk for Alzheimer's disease may benefit the most from healthy lifestyle interventions like walking, according to a decade of data from three large international studies. Older adults who carry the Alzheimer's risk gene known as APOE4 had higher cognitive benefits from non-drug interventions like exercise, diet and cognitive training than non-carriers. In this study, walking was found to be the most effective healthy habit for slowing down cognitive damage. Like many healthy lifestyle changes, the key was making it a habit, as the study showed that sticking with it for at least two years produced cognitive benefits up to seven years later. Participants in SNAP Food Assistance Program Had Slower Cognitive Decline People who participated in the U.S. Supplemental Nutrition Assistance Program (SNAP) had slower cognitive decline over 10 years than non-participants, according to new research reported at AAIC 2025. Scientists examined data from the nationally representative Health and Retirement Study to compare participants in SNAP, which helps low-income individuals and families buy food, to those who were eligible for the program but didn't participate. They found that SNAP participants had a 0.10% slower decline in overall cognitive function. The difference is significant in the long-term, adding up to an estimated two to three additional years of cognitive health over the study's 10-year period. The study group of 1,131 SNAP participants studied included Whites, Blacks and Hispanics. A control group included 1,216 people who were SNAP-eligible but didn't participate. Researchers found that all groups benefitted, but White participants showed much slower decline than other groups. The findings highlight the potential benefits of food assistance programs to support older adults' cognitive health. Real-World Results for New Alzheimer's Drugs Show Effectiveness, Patient Satisfaction While newly available anti-amyloid Alzheimer's disease drugs have shown effectiveness in tightly controlled clinical trials, they have not been tested in real-world settings until now. Dozens of abstracts reported at AAIC 2025 showed that real world experience with the drugs lecanemab and donanemab produced comparable or better safety to large clinical trials, and patients were satisfied with the results. Researchers tracked the drugs' safety and effectiveness in patients from a variety of settings including U.S. clinics, memory care centers and international universities. Several of the sites are part of the Alzheimer's Network for Treatment and Diagnostics (ALZ-NET), which was created by the Alzheimer's Association to collect voluntary real-world data about patients receiving the new treatments, track their long-term health, and share data with scientists and clinicians. New Insights Into Cognitive Health Differences Between Men and Women New research announced at AAIC 2025 sheds light on crucial differences between men and women in risk for Alzheimer's and other diseases that cause dementia. One study found that traumatic brain injuries (TBIs, a well-known risk factor for dementia) were more likely to shrink dementia-related areas of the brain in women than men. Another looked closer at "chemobrain" — declines in thinking and memory reported by about one-third of women receiving breast cancer chemotherapy. Women make up nearly two-thirds of the more than 7 million Americans living with Alzheimer's. The chemobrain study is the first to show that brain changes, inflammation and shrinkage related to the cancer treatment are connected to symptoms like memory lapses and trouble focusing or finding words. The study adds to growing evidence that chemotherapy impacts brain health. The Alzheimer's Association supports research to better understand sex-based differences in cognitive health and prevent negative side effects for chemo patients. Clinicians can learn more about early detection, diagnosis and treatment of dementia using ALZPro, the newly-launched library of online tools and resources for professionals from the Alzheimer's Association. The Alzheimer's Association extends a thank you to the AAIC 2025 Platinum Sponsors: Biogen, Eisai, Lilly and Novo Nordisk. About the Alzheimer's Association International Conference ® (AAIC ®) The Alzheimer's Association International Conference (AAIC) is the world's largest gathering of researchers from around the world focused on Alzheimer's and other dementias. As a part of the Alzheimer's Association's research program, AAIC serves as a catalyst for generating new knowledge about dementia and fostering a vital, collegial research community. AAIC 2025 home page: AAIC 2025 newsroom: AAIC 2025 hashtag: #AAIC25 About the Alzheimer's Association ® The Alzheimer's Association is a worldwide voluntary health organization dedicated to Alzheimer's care, support and research. Our mission is to lead the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer's and all other dementia ®. Visit or call 800.272.3900. SOURCE Alzheimer's Association
Cision Canada
5 days ago
- Cision Canada
Rocket Science Health Secures U.S Patent for Precision Intranasal Drug Delivery Platform
Patent covers a method of targeted drug delivery to the brain and central nervous system via subregions of the intranasal cavity Builds on recent corporate milestones and sets the stage for future strategic partnerships Advances Rocket Science Health's progression towards broader clinical applications VICTORIA, BC, July 30, 2025 /CNW/ - Rocket Science Health Corp., a Canadian healthcare technology company focused on precision drug delivery for brain therapeutics and vaccines, today announced it has secured U.S. Patent No. 12,343,489 from the United States Patent and Trademark Office for its investigational precision intranasal drug delivery device. The patent covers a method of targeted delivery of therapeutic compositions to subregions of the intranasal cavity, including the olfactory, dispensed from a vantage point that is essential for maximizing on-target and avoiding off-target delivery of drugs. "Getting drugs to the brain is one of medicine's hardest problems and our proprietary technology is designed to address that challenge – not just for brain delivery, but also for vaccines and other treatments that need more targeted approaches. It's not rocket science, but a simple drug delivery device that has the potential to make sophisticated drugs work, while broadening access to live-saving treatments," said Sohier Hall, President of Rocket Science Health. "The granting of these key patents is an important milestone on our journey to scale and accelerate the delivery of next-generation brain and central nervous system treatments, with the goal of initiating human clinical trials with our device in the near future." The upper nasal cavity offers a unique access point to the brain and central nervous system that can optimize the brain's exposure to drug therapies, accelerate the onset of action, reduce drug doses, improve the accuracy of delivery, and potentially improve health outcomes for millions of patients. However, commercially available nasal spray devices can only deliver a fraction of their dose volume to the olfactory region due to the anatomical characteristics of the nasal cavity. At the same time, nearly all small and large molecule drug therapies approved by the FDA cannot enter the central nervous system when taken through other, traditional routes of administration. Initial peer-reviewed research and in-human imaging studies have validated Rocket Science Health's patented technology and demonstrated precise, repeatable drug deposition to subregions of the intranasal cavity. This technology is compatible with delicate drug formulations, including lipid nanoparticles (LNPs), biologics, peptides, and can handle a range of viscosities. The Company is evaluating licensing of its technology to developers where precision delivery is a potential factor for success in their pending clinical trial. The intellectual property applies to both next-generation therapies or reestablishing existing molecules with greater effect and patent ability. With strong intellectual property, validated in-human results, and industry-leading execution partners in place, Rocket Science is well-positioned to advance toward broader clinical applications in brain-targeted drug delivery. For more information on Rocket Science Health, visit About Rocket Science Health: Rocket Science Health, founded by Canadian business leader Kenneth Irving, develops precision drug delivery technologies focused on brain-targeted therapeutics and vaccines. Our needle-free intranasal device enables non-clinical self-administration for at-home care, emergency rescue, and mass immunization. Its fluidics are specifically engineered for today's delicate biologics and dose-dependent drugs. As a team, we are driven to create innovations that expand access to care—especially for under-resourced communities and for individuals who face physical, cognitive, or challenging care environments where thoughtful design can improve health outcomes.
